No results for ‘’
Samrat Pharmachem Ltd
₹225.95
(0.67%)
Thu, 24 Sept 2026, 05:48 am
Process Industries
Chemicals: Specialty
24.5KSamrat Pharmachem Debt to Equity Ratio
| Particulars | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 0 | 3.84 | 4.21 | 2.46 | 16.15 | 25.90 | 36.08 | 27.50 | 13.91 | 12.15 | 15.02 | 4.37 | 7.88 | 8.72 | 6.89 | 47.64 | 13.59 |
| Price to book ratio | 0.39 | 0.59 | 0.65 | 0.74 | 0.50 | 0.48 | 0.85 | 0.61 | 1.59 | 2.11 | 1.15 | 0.76 | 1.42 | 3.20 | 1.82 | 1.59 | 1.35 |
| Price to sales ratio | 0.07 | 0.10 | 0.13 | 0.13 | 0.09 | 0.10 | 0.24 | 0.13 | 0.34 | 0.42 | 0.21 | 0.13 | 0.23 | 0.68 | 0.37 | 0.37 | 0.34 |
| Price to cash flow ratio | 5.78 | 4.71 | 0 | 2.34 | 0 | 1.53 | 0 | 6.43 | 0 | 0 | 16.28 | 0 | 11.56 | 8.84 | 0 | 11.34 | 0 |
| Enterprise value | 1.87Cr | 2.91Cr | 5.78Cr | 8.26Cr | 8.23Cr | 5.03Cr | 10.68Cr | 8.39Cr | 24.19Cr | 44.49Cr | 27.35Cr | 26.74Cr | 48.27Cr | 143Cr | 121Cr | 102Cr | 106Cr |
| Enterprise value to EBITDA ratio | 4.22 | 1.51 | 2.40 | 1.38 | 7.63 | 8.35 | 9.13 | 7 | 6.54 | 7.57 | 8.67 | 4.06 | 5.40 | 5.85 | 5.02 | 36.10 | 9.94 |
| Debt to equity ratio | 0.38 | 0.22 | 0.22 | 0.27 | 0.35 | 0.24 | 0.24 | 0.40 | 0.45 | 0.51 | 0.33 | 0.39 | 0.30 | 0.16 | 0.30 | 0.13 | 0.14 |
| Return on equity % | 0 | 16.54 | 16.68 | 35.61 | 3.15 | 1.86 | 2.38 | 2.21 | 12.07 | 19 | 7.96 | 19.10 | 19.77 | 44.95 | 30.25 | 3.38 | 10.40 |
Samrat Pharmachem Ltd Debt to Equity Ratio
The Samrat Pharmachem Ltd Debt to Equity Ratio is a key financial metric used by investors to evaluate Samrat Pharmachem Ltd's valuation, profitability, and overall financial performance. Tracking the Samrat Pharmachem Ltd Debt to Equity Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Samrat Pharmachem Ltd (NSE: , BSE: 530125) is currently trading at ₹225.95, with a market capitalization of ₹69.35Cr. As a leading company in the Process industries sector and Chemicals: specialty industry, monitoring the Samrat Pharmachem Ltd Debt to Equity Ratio is essential for fundamental analysis.
Samrat Pharmachem Ltd Debt to Equity Ratio Current Value
The current Samrat Pharmachem Ltd Debt to Equity Ratio stands at 0.14.
The latest Samrat Pharmachem Ltd Debt to Equity Ratio has increased compared to the previous period, indicating rising valuation or improved investor sentiment.
Samrat Pharmachem Ltd Debt to Equity Ratio Historical Trend
The Samrat Pharmachem Ltd Debt to Equity Ratio has shown the following historical trend:
- 2024: 0.14
- 2023: 0.13
- 2022: 0.30
- 2021: 0.16
- 2020: 0.30
The recent rise in Samrat Pharmachem Ltd Debt to Equity Ratio suggests strengthening valuation trends and improving market sentiment.
What Samrat Pharmachem Ltd Debt to Equity Ratio Indicates for Investors
The Samrat Pharmachem Ltd Debt to Equity Ratio plays a crucial role in understanding the company's financial health and valuation.
The D/E ratio measures financial leverage and balance sheet strength.
Samrat Pharmachem Ltd Debt to Equity Ratio Analysis Summary
The Samrat Pharmachem Ltd Debt to Equity Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Samrat Pharmachem Ltd Debt to Equity Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Samrat Pharmachem Ltd Debt to Equity Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.